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(PaVOS)- study protocol for a randomized
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Abstract
Background: PaVOS is a randomized controlled trial (RCT) which aims to address the use of whole-body vibration
exercise (WBV) in combination with parathyroid hormone 1-34 fragment teriparatide (PTH 1-34) treatment in
patients with osteoporosis. PTH 1-34 is an effective but expensive anabolic treatment for osteoporosis. WBV has
been found to stimulate muscle and bone growth. Animal studies have shown a beneficial effect on bone when
combining PTH 1-34 with mechanical loading. A combined treatment with PTH 1-34 and WBV may potentially have
beneficial effects on bone and muscles, and reduce fracture risk.
Methods/design: PaVOS is a multicenter, assessor-blinded, superiority, two-armed randomized controlled trial (RCT).
Postmenopausal women (n = 40, aged 50 years and older) starting taking PTH 1-34 from outpatient clinics will be
randomized and assigned to a PTH 1-34 + WBV-exercise group (intervention group), or a PTH 1-34-alone group
(control group).
The intervention group will undergo WBV three sessions a week (12 min each, including 1:1 ratio of exercise: rest, 30
Hz, 1 mm amplitude) for a 12-month intervention period. Both the intervention and the control group will receive PTH
1-34 treatment (20 μg s.c. daily) for 24 months. After 12 months the WBV group will be re-randomized to stop or
continue WBV for an additional 12 months.
The primary endpoint, bone mineral density (BMD), will be measured by dual-energy x-ray absorptiometry of the total
hip and the lumbar spine.
Secondary endpoints, bone microarchitecture and estimated bone strength, will be assessed using high-resolution
peripheral quantitative computed tomography (HR-pQCT) of the radius and tibia. Serum bone turnover markers
(carboxy-terminal collagen crosslinks (CTX), amino-terminal propeptide of type-I collagen (P1NP), and sclerostin) and
functional biomarkers (Timed Up and Go (TUG), Short Physical Performance Battery (SPPB), grip strength, and leg
extension power) will be measured to assess the effect on bone turnover, muscle strength, balance, and functionality.
Quality of life (EQ-5D), physical activity (IPAQ) and fear of falling (FES-I) will be assessed by questionnaires. Data on
adherence and falls incidence will be collected.
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* Correspondence: Ditte.Beck.Jepsen2@rsyd.dk
1Department of Geriatric Medicine, Odense University Hospital, Odense,
Denmark
2Institute of Clinical Research, Faculty of Health Science, University of
Southern Denmark, Odense, Denmark
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Jepsen et al. Trials  (2018) 19:186 
https://doi.org/10.1186/s13063-018-2551-5
(Continued from previous page)
Discussion: The PaVOS study will investigate the effects of WBV in combination with PTH 1-34 on bone parameters in
postmenopausal women.
Trial registration: ClinicalTrials.gov, ID: NCT02563353. Registered on 30 September 2015.
Keywords: Osteoporosis, Whole-body vibration, Parathyroid hormone, Teriparatide, Bone mineral density, Bone quality, RCT
Background
Introduction
Osteoporosis is defined by the World Health
Organization (WHO) as a disease with low bone mass
and impaired microarchitecture leading to a high risk of
fragility fractures [1].
Fragility fractures of the hip are associated with sig-
nificant morbidity, institutionalization, and a 1-year
mortality of > 20% [2]. Vertebral fractures are also as-
sociated with osteoporosis and can lead to significant
pain, disability, morbidity, and reduced quality of life
[3]. Osteoporotic fractures cause a significant disease
burden in developed countries [4] and a recent study
of the societal burden imposed by osteoporotic frac-
tures in Denmark showed an estimated yearly cost of
€1.563 billion [5].
The parathyroid hormone 1-34 fragment teriparatide
(PTH 1-34) is the most commonly used anabolic agent
for the treatment of osteoporosis. The Fracture Preven-
tion Trial showed that PTH 1-34 significantly reduced
the incidences of vertebral and non-vertebral fractures
[6]. However, the relatively high cost of PTH 1-34
(€7103 per year) restricts its use in osteoporotic patients
to those with the highest fracture risk or, those who had
inadequate response to, or cannot tolerate more com-
monly used anti-osteoporotic agents, such as bispho-
sphonates [7]. Thus, any intervention that can boost the
efficacy of PTH 1-34 could make it more cost-effective.
Furthermore, as the length of PTH 1-34 treatment is
limited (licensed for up to 18–24 months only), and
maximizing its response by such augmentation would be
desirable, in terms of reducing fracture risk in individual
patients and by potential cost-saving implications.
Mechanical loading is also known to increase bone
formation and load-bearing exercise is an important
component in maintaining and improving bone health.
Studies have shown that load-bearing exercise can in-
crease bone mineral density (BMD) [8].
A synergistic or additive effect of combined PTH
1-34 treatment and mechanical loading has been re-
ported [9, 10]. Not all older people, however, can
undertake high-intensity or weight-bearing exercise.
A proposed alternative is whole-body vibration
(WBV) therapy which, like weight-bearing exercise,
stimulates muscles and bones. In some studies, WBV
increases the anabolic (bone-building) effects in bone
tissue, as well as increasing BMD [11, 12]. One hy-
pothesis suggests that the effects of vibration directly
activate mechanosensors in bone cells [13]. Like
weight-bearing exercise [14], WBV may thus improve
muscle strength and power by increasing neuromus-
cular activation [15]. In healthy volunteers, the ef-
fects of vibration therapy on muscle strength and
performance were similar to those of short-term re-
sistance exercise [14].
WBV therapy may also improve blood circulation in
muscle and bone and increase the supply of nutrients
needed to build bones [16]. Platforms for WBV are
now commercially available and are used in gyms, as
an alternative form of exercise. Animal studies with
the combination of PTH analogs and WBV are few and
with diverse results. One study with low-magnitude vi-
bration and PTH 1-34 in mice showed no synergy in
increasing bone mineral content after 8 weeks of treat-
ment [17]. A recently published study showed that the
combination of noise-like WBV and PTH treatment of
fracture healing produced an additive effect in increas-
ing bone formation and enhancing the mechanical
function of the bone [18]. Human studies have shown
that vibration can be anabolic to bone [12, 19, 20], and
a study performed by one of our group (TM) has
shown that WBV is well tolerated even by frail, older
individuals and increases muscle strength and bone-
formation markers [19]. Adding mechanical loading in
the form of WBV to the treatment with an anabolic
agent may improve treatment outcomes further in-
creasing BMD and reducing the risk of fracture.
Study objectives
To determine if WBV in addition to standard PTH 1-34
treatment has a greater effect in osteoporotic patients
compared to standard PTH 1-34 treatment alone on:
BMD
Bone microarchitecture
Markers of bone formation and resorption
Muscle function and balance
To assess the safety and adherence to WBV in
osteoporotic patients
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Methods/design
General design
This will be a multicenter, assessor-blinded, super-
iority, two-armed RCT in osteoporotic patients start-
ing standard PTH 1-34 treatment. In Denmark, PTH
1-34 is used for the treatment of severe osteopor-
osis, and the cost is reimbursed if patients have a
lumbar spine or total hip T-score ≤ − 3 combined
with at least one clinical vertebral fracture (compres-
sion ≥ 25%) within the past 3 years or at least two
vertebral fractures (compression ≥ 25%) independ-
ently of BMD. Participants will be randomized to
PTH 1-34 treatment alone or to combined PTH 1-
34 treatment and WBV (see Fig. 1). The study will
be reported according to the Consolidated Standards
of Reporting Trials (CONSORT) extension to non-
pharmaceutical interventions and the Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) 2013 Checklist for RCTs (Additional
file 1).
Participants
Postmenopausal women over the age of 50 years attend-
ing either of the following outpatient clinics will be re-
cruited: the Osteoporosis Clinics at Odense University
Hospital (Svendborg or Odense), the Department of
Geriatrics at Odense University Hospital, the Depart-
ment of Endocrinology at Hospital of Southwest
Denmark, the Department of Endocrinology at Hospital
Lillebaelt or the Department of Endocrinology and
Internal Medicine, Aarhus University Hospital.
Inclusion criteria
Postmenopausal women aged ≥ 50 years starting PTH
1-34 treatment for osteoporosis
Fig. 1 The Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Figure with the schedule of enrollment, interventions, and
assessments. BMD bone mineral density; Bone turnover biomarkers procollagen type-1 amino-terminal propeptide, carboxy-terminal type-1
collagen crosslinks, sclerostin; HR-pQCT high-resolution peripheral quantitative computed tomography; FES-I Falls Efficacy Scale International;
Functional biomarkers: Short Physical Performance Battery, Timed Up and Go, grip strength, leg extension power; IPAQ International Physical
Activity Questionnaire.
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Exclusion criteria
Currently taking oral glucocorticoids
Unable to give informed consent
Unable to stand for 1 min at a time on the vibration
platform
Contraindications to WBV (e.g., joint prosthesis,
pacemakers)
Intervention
After instructions by nurses in the treating clinics all
participants will self-administer subcutaneously (s.c)
PTH 1-34 (20 μg s.c. daily) during the study. The partici-
pants follow each clinic’s control program including
measurements of serum calcium and creatinine through-
out the study. Medical records will be used to check the
adherence to the PTH 1-34 treatment.
Half of the participants will be randomized to an inter-
vention group, receiving WBW as add-on treatment.
WBV will be undertaken using power plate My5 (Power
plate®, UK). The power plate machine oscillates in all
three planes, with a frequency of 30 Hz and amplitude
of 1 mm (low displacement) and peak acceleration of
35.53 ms-2 rms (3.6 g).
The WBV intervention will be performed three times
a week according to a training protocol (Table 1). The
vibration platforms will be delivered and installed in the
participant’s own home and instructions for use and the
training program will be given by one of the investiga-
tors (DJ).
The WBV intervention will be conducted with the
knees slightly bent (at approximately 20°) to prevent vi-
brations to cause side effect as dizziness from the vibra-
tion transmitted to the head. The training period will be
followed by a resting period in the ratio 1:1 and the
training days will be conducted with a resting day in
between.
Randomization
After informed consent and collection of baseline data, par-
ticipants will be randomized into two groups: PTH 1-34
treatment alone or PTH 1-34 treatment + WBV (Fig. 2).
The randomization is a web-based, computer-generated
block randomization with no stratification. Block size is
created by a data manager and the size is unknown to the
investigators until the end of the study. Allocation will be
concealed to the participants and the investigators until
after collection of baseline data.
After 12 months the combined PTH 1-34 + WBV
group will be re-randomized to continuation of com-
bined PTH 1-34 + WBV for another 12 months, or to
PTH 1-34 alone (i.e., stopping WBV) for another 12
months. This will allow us to determine if any positive
effects of WBV wear off after it has been stopped or if
any gains persist.
Endpoints
Primary endpoints
The primary endpoint is the percent change in areal
BMD of total hip and lumbar spine as measured by
dual-energy x-ray absorptiometry (DXA) (Hologic Dis-
covery, Waltham, MA, USA) from baseline until 12
months (Table 2).
BMD is chosen as an endpoint since it is an important
determinant of fracture risk and is used to diagnose and as-
sess response to treatment in osteoporotic patients [1, 21].
Secondary endpoints
Bone mass Change in areal BMD of total hip and lum-
bar spine is measured by DXA from baseline until 6, 18,
and 24 months (Table 2).
Bone microarchitecture Images from high-resolution
peripheral quantitative computed tomography (HR-
pQCT) (Xtreme CT, Scanco Medical, AG, Brüttisellen,
Switzerland), of the non-dominant distal radius and dis-
tal tibia (the opposite limb in the presence of a previous
fracture) will be obtained to measure bone geometry,
cortical morphology, trabecular morphology, and overall
biomechanical competence. In in-vitro studies estimated
bone strength of the radius using finite element analysis
[22, 23] which has been shown to be more closely corre-
lated to observed radius bone strength than areal BMD
by DXA [22]. PTH 1-34 treatment has been shown to be
associated with an increase in vertebral estimated bone
strength [24] and preservation of the estimated bone
strength of the radius and hip [25, 26]. The images are
Table 1 Training protocol
Week First training day Second training day Third training day
1 30 s × 2 30 s × 3 30 s × 4
2 1 min × 1 1 min ×2 1 min × 3
3–5 1 min × 4 1 min × 4 1 min × 4
6–7 1 min × 5 1 min × 5 1 min × 5
8 to the end of study 1 min × 6 1 min × 6 1 min × 6
Min minutes, s seconds
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Fig. 2 Timeline for participants. Figure 2 shows the timeline for the participants in the study. The x-axis is the time during the study in months.
The participants will be randomized after baseline data is collected to an intervention group receiving whole-body vibration (WBV) in addition to
PTH 1-34 compared to the control group receiving PTH 1-34 alone. After 12 months the intervention group will be re-randomized. BMD bone
mineral density; HR-pQCT high-resolution peripheral quantitative computed tomography; Bone biomarkers procollagen type-1 amino-terminal
propeptide (P1NP), carboxy-terminal type-1 collagen crosslinks (CTX), and sclerostin; Physical markers: Timed Up and Go (TUG), Short Physical
Performance Battery (SPPB), grip strength and leg extensor power; DXA dual-energy x-ray absorptiometry; IPAQ The International Physical Activity
Questionnaire; FES-I Falls Efficacy Scale International
Table 2 Primary and secondary endpoints
Measurement Site Time (months)
Primary endpoints
Δ Bone mineral density DXA Total hip
Spinal region
12
Secondary endpoints
Δ Bone mineral density DXA Total hip
Spinal region
6, 18, and 24
Δ Bone microarchitecture HR-pQCT Distal radius
Distal tibia
6, 12, 18, and 24
Δ Bone biomarkers P1NP
CTX, sclerostin
Serum 3, 6, 12, 18, and 24
Δ Physical biomarkers TUG
SPPB
3, 6, 12, 18, and 24
Dynamometer Hand grip
Nottingham power rig Leg extensor
Δ Quality of life EQ-5D 12 and 24
Δ Fear of falling FES-I 12 and 24
Physical activity IPAQ 0, 12, and 24
Adherence to WBV Training logbook Continuously
Falls Falls calendar Continuously
Δ change from baseline; Time is measured in months; DXA dual-energy x-ray absorptiometry; HR-pQCT high-resolution peripheral quantitative computed
tomography; P1NP procollagen type-1 amino-terminal propeptide; CTX carboxy-terminal type-1 collagen crosslinks; TUG Timed Up and Go; SPPB Short Physical
Performance Battery; FES-I Falls Efficacy Scale International; IPAQ The International Physical Activity Questionnaire; EQ-5D EuroQoL 5-dimension,
5-level questionnaire, WBV whole-body vibration
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obtained at baseline, 6, 12, 18, and 24 months (Table 2).
The reported outcomes will be total BMD, cortical thick-
ness, cortical porosity, bone volume per trabecular vol-
ume (BV/TV), trabecular number, trabecular thickness,
and finite element failure load. The scanning protocol
and the image acquisition have previously been
described in detail [22, 23].
Serum bone turnover markers Markers of bone forma-
tion (procollagen type-1 amino-terminal propeptide
(P1NP)) and bone resorption (carboxy-terminal type-1
collagen crosslinks (CTX-1) will be measured by the
method of chemiluminescence (iSYS, Immunodiagnostic
Systems Ltd., Boldon, England). Sclerostin is analyzed
using TECOmedical Human Sclerostin HS ELISA
(TECOmedical group, Sissach, Switzerland). Bone turn-
over is affected by treatment with PTH 1-34, and studies
have shown that a rise in the marker of bone formation,
P1NP, during PTH 1-34 treatment is a predictor of the
increase in BMD [27]. The assessment of bone bio-
markers will allow exploration of mechanisms of action
of WBV in augmenting PTH 1-34 treatment on bone
turnover. The blood samples are taken at baseline, 3, 6,
12, 18, and 24 months (Table 2) after an overnight fast
and stored at − 70 °C until analyzed in a central
laboratory.
Functional biomarkers Functional biomarkers includ-
ing measurements of muscle strength, function and bal-
ance is measured by: (1) Timed Up and Go (TUG), (2)
Short Physical Performance Battery (SPPB), (3) leg ex-
tensor power (Nottingham power rig), and (4) grip
strength (Smedley dynamometer, TTM, Tokyo, Japan).
Fragility fractures are most often associated with falls
[21, 28]. The measurement of lower extremity function
and mobility will indicate if WBV has the potential to
reduce the risk of falls in osteoporotic patients, which is
another important determinant of the risk of fracture,
independent on the effects on bone [21]. The TUG is
the measurement of functional mobility and is a simple
and reliable clinical test used to screen for fall risk in
community-dwelling older persons [29]. Lower-
extremity function and balance can also be assessed by
the SPPB which is a validated test in older adults [30].
Leg extension power is assessed using a leg extensor
power rig, (Medical Engineering Unit, School of
Biomedical Sciences, University of Nottingham Medical
School, Nottingham, UK) reported to have good reliabil-
ity with no significant differences found between two
tests performed 1 week apart (r = 0.97; coefficient of
variation = 9%) [31]. At each visit the same leg is tested
with a series of five measurements from the same start-
ing position. The leg is selected randomly at the first
visit. The SPPB and the TUG are described in detail by
others [30, 32]. Reduced grip strength is a predictor of fra-
gility fractures independent of BMD [33]. A reliable and
valid method is by using a Smedley dynamometer (TTM,
Tokyo, Japan). The measurements are done twice with
each hand using a protocol described by others [34].
The functional tests will be performed by technicians,
who all have been trained by a physiotherapist and all
tests are conducted by standardized protocols. The
TUG, SPPB, grip strength and leg extension power tests
will be performed at baseline, 3, 6, 12, 18, and 24
months (Table 2).
Full-body DXA (Hologic Discovery, Waltham, MA,
USA) is performed at baseline, 12, and 24 months to as-
sess muscle mass (Fig. 2).
Sarcopenia is a condition with low skeletal muscle
mass leading to decreased muscle strength, and impaired
physical function, associated with an increased risk of
falls [35]. Sarcopenia is proposed to be assessed by a var-
iety of measurements of muscle mass and function in-
cluding but not limited to full-body DXA, SPPB, grip
strength, and gait speed [36, 37].
Questionnaires The participants’ physical activity will
be measured by a validated questionnaire, the Inter-
national Physical Activity Questionnaire (IPAQ). The
participants’ multiples of the resting metabolic rate will
be generated (MET-min/week) [38].
Vertebral fractures have been shown to decrease qual-
ity of life [3] and the EuroQol 5-dimension, 5-level ques-
tionnaire (EQ-5D) is a well-validated measure of quality
of life [39, 40].
The patients’ own fear of falling is associated with the
risk of falls [41] and the the Falls Efficacy Scale Inter-
national (FES-I) questionnaire, which is a reliable and
validated questionnaire to measure the fear of falling in
an older population [42].
The questionnaires IPAQ, EQ-5D, and FES-I will be
distributed in paper versions to the participants at base-
line, 12, and 24 months.
Adherence Adherence to WBV is ascertained using
self-reported adherence in a log book. Dropouts and the
reasons for this will be noted. The adherence to the
PTH 1-34 treatment is ascertained by asking the patients
and by using the prescription database.
Side effects Information on symptoms of dizziness,
pain, and falls will be collected. The participants will be
handed a calendar to note fall events, defining a fall as
“an unexpected event in which the participants come to
rest on the ground, floor, or lower level” [43]. Pain will
be assessed by the Numeric Rank Score (0 being no
pain, and 10 being unbearable pain) and the question
about how many days they have felt dizzy during the last
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week, and falls will be assessed by monthly telephone
calls during the first year and then every 3 months for
the rest of the trial.
Demographic data, including data on risks factors as-
sociated with osteoporosis and fragility factures, will be
collected at baseline and thus before randomization.
These factors include Body Mass Index, current and
previous height, age, comorbidity, fall history, previous
fractures, vitamin D and calcium intake, current, and
previous history of medication.
Statistical analysis
Sample size determination
The inclusion of 32 participants (16 in each group)
would give the study 80% power to detect a clinically
significant additional increase of 22% in BMD with
WBV (assuming a 9% increase of BMD in the PTH 1-
34-alone group and 11% increase in the combined PTH
1-34 + WBV group, and assuming a standard deviation
(SD) of the BMD increase of 2% [12]. Inclusion of 40
participants (20 in each group) will allow for a 20%
dropout rate.
Statistical methods and data managing
The intervention arm (PTH + WBV) is compared
against the control arm for all primary analyses. We will
use analysis of covariance (ANCOVA) and “percentage
change” for primary outcome adjusting for baseline mea-
surements. For secondary outcomes we will use a chi-
squared test for binary outcomes, analysis of variance
(ANOVA) and the T test for continuous outcomes, and
for non-normally distributed continuous outcomes we
will use log transformation or Wilcoxon’s match-pairs
signed-rank test and the Kruskal-Wallis test.
All p values will be reported to four decimal places
with p values < 0.001 reported as p < 0.001. STATA ver-
sion 14 will be used to conduct analyses. For all tests, we
will use two-sided p values with an alpha ≤ 0.05 level of
significance.
The analyses will be conducted with the intention-to-
treat method, and in order to investigate the effect of ad-
herence and withdrawal a per-protocol analysis will be
conducted. Missing data will be handled using multiple
imputation. Study data is collected and managed using
REDCap (Version 6.5.10 – © 2015 Vanderbilt University)
electronic data capture tools hosted at the University of
Southern Denmark [44]. Sequential study numbers will
be allocated to study patients and entered into the re-
cruitment log at the secure web database REDCap.
Discussion
This is a RCT in osteoporotic patients randomized to
PTH 1-34 treatment alone or to combined PTH 1-34
treatment and WBV. The primary and secondary
endpoints in the study are chosen because previous
studies have shown such markers of bone mass, micro-
architecture, and turnover, as well as indices of physical
performance, to be associated with osteoporosis or
fragility fractures.
Earlier studies have reported WBV as a feasible inter-
vention [12] and in older patients the adherence is
reported to be good [19].
The intervention is designed to be of long duration
(12–24 months) and the setting at the participants’ own
home makes the training easy and highly accessible.
The study has limitations including the non-blinded
design. It is our hypothesis that the primary endpoint,
the BMD as well as a number of secondary endpoints
(bone microarchitecture and bone turnover markers) are
not at risk of bias by the open-label design. The func-
tional biomarkers on the other hand could be affected
by the non-blinded design but the study personnel per-
forming the tests are blinded to the allocation and the
baseline data is collected before randomization.
Measurements of quality of life, physical activity, and
the FES-I questionnaire are patient-collected data,
resulting in the possibility of bias in the reporting.
To limit the possibility of bias by attention, the
participants will receive close to an equal amount of
contacts by the investigators because of the “at home
training design.”.
The study is partially blinded and is protected against
selection bias by central randomization after baseline
measurements, randomization via web with no stratifica-
tion, and by allocation concealment.
It is our hypothesis that the DXA, HR-pQCT, and
bone marker measurements are not at risk of perform-
ance bias. The physical biomarkers may be prone to per-
formance bias, but the test personnel will be blinded to
avoid evaluation bias.
To avoid attrition in both arms and ensure adherence,
the participants are contacted by telephone each month
during the first year and every third month during the
second year. The participants receive a direct telephone
number and mailing address to the primary investigator
and are encouraged to make contact in case of any ques-
tions or events.
Every patient is motivated to attend follow-up regard-
less of randomization or adherence. The participants do
not receive payment but are reimbursed for transport
expenses.
The adherence to the training protocol is patient re-
ported data and is in risk of reportingbias. A previous
study nevertheless found high correlation with the usage
of a training logbook to electronic monitoring in the
WBV intervention in older adults (overall intraclass cor-
relation coefficient = 0.96), showing a small risk of bias
in the collected data on adherence [45].
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A combined treatment of WBV and PTH 1-34 might
have synergistic or additive beneficial effects on bone
strength, thereby reducing fracture risk and making the
treatment more cost-effective. A beneficial effect of
WBV on muscles, and subsequently fall risk, may lower
the fracture risk even further, resulting in comprehensive
fracture prevention.
Trial status
Recruitment of participants started in November 2015
and will be completed in September 2017. This study
has been registered at ClinicalTrials.gov (September,
2015: NCT02563353).
Additional file
Additional file 1: SPIRIT 2013 Checklist: recommended items to address
in a clinical trial protocol and related documents*. (DOC 124 kb)
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